Introduction {#s0005}
============

Targeting oncogene-driven signaling pathways is a clinically validated approach for treating several devastating diseases. Gefitinib is a selective inhibitor of epidermal growth factor receptor (EGFR) mutation and constitutes a paradigm shift in lung adenocarcinoma (LAD) therapy [@b0005]. Unfortunately, acquired resistance and early relapses, which unavoidably occur, represent a major limitation to clinical responses [@b0010]. To explain this phenomenon, the cancer stem cell (CSC) hypothesis suggests that tumors contain a small number of tumor-forming and self-renewing stem cells that are less responsive to gefitinib and other tyrosine kinase inhibitors (TKIs) and constitute a critical target population for acquisition of drug resistance [@b0015], [@b0020], [@b0025]. Therefore, strategies to prevent the re-emergence of CSCs have been devised to augment the impact of anticancer therapy.

The comprehensive evidence for bioenergetic metabolism reprogramming of tumor cells has received increased attention during the previous decade [@b0030]. Studies demonstrated mitochondria-specific oxidative features as a specific vulnerability of cells exhibiting therapy selective quiescence (TSQ), which when exploited, should be amendable to established cytotoxic interventions and provide the basis for developing more effective therapies to combat lethal disease [@b0035], [@b0040]. Minimally, this would apply to lymphomas undergoing TSQ in response to cytotoxic therapy [@b0035], minimal residual leukemia resistant to TKIs [@b0045], slow-cycling melanoma cells selected for a JARID1B^high^ phenotype by cytotoxic agents [@b0050], *BRAF*-mutant melanomas escaping therapy with BRAF inhibitors [@b0055], and a subpopulation of dormant pancreatic cancer cells surviving *KRAS* oncogene ablation [@b0060]. These examples strongly suggest that reliance on mitochondrial metabolism might represent a measure of "druggable" susceptibility by multidrug-resistant cancers. Comprehensive evidence for a mitochondrial role in LAD cells exhibiting TSQ and the genes responsible for this process is inconclusive [@b0065], [@b0070].

The nicotinamide adenine dinucleotide (NAD)-dependent histone deacetylase sirtuin 1 (SIRT1) is a nuclear protein expressed in almost all cell types and that plays a major role in stemness maintenance and TKI resistance, as well as being involved in modulating gene expression, aging, development, and many metabolic and stress-response pathways [@b0075], [@b0080], [@b0085].

The aim of this study was to elucidate the mechanism(s) involved in cellular perturbations accompanying acquired gefitinib resistance in order to provide new therapeutics to target TSQ cells and achieve therapy free remission in LAD patients. Additionally, we evaluated new possibilities of the synergism of tenovin-6 (TV-6) [@b0090], [@b0095], [@b0100], a small-molecule compound that inhibits SIRT1, with reduced doses of conventional cytotoxic therapies currently ineffective as monotherapies for future application in clinical settings to treat LAD.

Materials & Methods {#s0010}
===================

Study participants {#s0015}
------------------

From 2007 to 2014, a multicenter research of lung adenocarcinoma drew subjects primarily from the Taihang Mountain region of Henan provinces, including the First Affiliated Hospital of Henan University of Science and Technology (HUST; Luoyang, Henan, China) and Anyang Tumor Hospital (ATH; Anyang, Henan, China). Tumor specimens containing the EGFR exon 19 deletion or L858R sensitive mutation were obtained with informed consent in accordance with the institutional review boards at HUST and ATH. Treatment naïve patients had a core biopsy from the primary lung tumor or surgical resection; and patients that relapsed under Gefitinib had a fine needle biopsy from a primary tumor or metastasis. All patients had an initial partial response, followed by disease progression after 120 days of Gefitinib therapy. The presence of EGFR mutations in each specimen was determined by PCR-based direct sequencing. No restrictions regarding age, sex, or disease stage were set. Patients who had received any preoperative radio-, chemo- or immune- therapy before recruitment were excluded. Each specimen was sufficient to be cut into pieces and treated differently for various uses, put in liquid nitrogen to extract RNA for RNA sequencing, or fixed in 10% formaldehyde for making paraffin embedded blocks. Additional fresh LAD specimens were collected, for isolation and identification of ALDH1^bri+^ cells or generation of patient-derived xenografts (PDXs).

High-throughput RNA sequencing and data analysis {#s0020}
------------------------------------------------

The constructed libraries were sequenced using an Illumina HiSeq 2500 system (Illumina). Low-quality reads, short reads, rRNAs, and reads containing primer/adaptor contamination were removed. The remaining high-quality reads were mapped to a reference genome (mm10) with two mismatches using Tophat (v.2.0.9; <https://ccb.jhu.edu/software/tophat/index.shtml>), and results were expressed as fragments per kilobase of transcript per million mapped reads (FPKM). The genes in the libraries were produced using the Cufflinks tool (v.2.1.1; <http://cole-trapnell-lab.github.io/cufflinks/>) according to the reference annotation set (mm10). Fold changes for the genes in different samples were estimated based on their FPKM values, and the significance threshold was determined according to the false discovery rate (FDR). In this study, a differentially expressed gene was defined as a gene whose expression changed more than two-fold among the different samples with an FDR ≤ 0.05.

Gene set enrichment analysis (GSEA) {#s0025}
-----------------------------------

Ranked lists of differentially expressed genes (fold change ≥ 1.5; *t* test *p* ≤ 0.05) were assessed through the GSEA desktop application using the GSEAPreranked tool (<http://software.broadinstitute.org/cancer/software/genepattern/modules/docs/GSEAPreranked/1>). Curated gene sets (C2) from the Molecular Signatures Database (v5.0; <http://software.broadinstitute.org/gsea/msigdb/index.jsp>) were interrogated, and after filtering out genes not in the expression dataset, gene sets of \<15 genes or \>3000 genes were excluded from analysis. GSEA was run using 1000 gene-set permutations to generate FDRs. Default settings were used for normalizing the enrichment scores (NES).

In vivo studies {#s0030}
---------------

We used a patient-derived xenograft (PDX) model, in which 1- to 2-mm fragments of tumors from post-relapsed LAD patients under gefitinib treatment were orthotopically implanted into the mammary fat pad of NOD/SCID interleukin-2 receptor-γ chain-deficient (NSG) mice. After implantation, the mice were randomly divided into four different groups (*n* = 10/group) and treated 14 days later for a period of 3 weeks by intraperitoneal (i.p.) injection with gefitinib (100 mg/kg, daily), TV-6 (50 mg/kg, daily), both drugs combined, and vehicle only twice daily. The animals dosed according to the appropriate scheme were monitored daily for up to 3 months, and the objective response rate and survival were recorded. An additional cohort of mice (*n* = 3/group) was included to conduct mechanistic studies. In this cohort, the mice were sacrificed on day 40 post-drug administration, and residual tumors were surgically removed before terminal escape \[tumor with partial response (PR); TV-6 therapy\] or complete remission \[tumor with complete response (CR); combined therapy\]. Resected tumors were processed for Aldefluor assay and flow cytometric analysis. Flow cytometry results related to the aldehyde dehydrogenase 1 (ALDH1)^bri+^ fraction were determined, and a representative mouse from each treatment group in this separate cohort is shown. For studies on tumor re-challenge, 1- to 2-mm diameter pieces of tumor taken from residual tumors surgically removed on day 25 post-drug administration were implanted into another cohort of NSG mice (*n* = 5/group), and the engraftments were recorded. CR was defined as complete regression of the tumor without any recurrence. Primary and secondary challenge tumor growth was followed for up to 90 and 28 days, respectively. Tumor growth was monitored by caliper measurements, and tumor volume (TV) was calculated as follows: TV (mm^3^) = π/6 × length × width^2^. Treatment with gefitinib, TV-6, and their combination was conducted twice daily due to toxicity to TV-6 and deviation from design of the animal study. Mice suffering from progressive disease or those used for subsequent analysis were euthanized when TV was \>2500 mm^3^. The health status and weight of the mice was monitored daily, and mice were humanely euthanized when moribund, as defined by weight loss exceeding 10% to 15%, lethargy, ruffled fur, and/or partial or hind-limb paralysis. At the end of the measurement, mice were sacrificed, venous blood was drawn from the orbit of the mice for confirmation of drug tolerability, and serum levels of liver, muscle, or cardiac enzymes were determined.

Six-to 8-week-old male nude mice were implanted subcutaneously with a total of 5 × 10^6^ PC9 green fluorescent protein (GFP)^+^ cells, administered luciferin i.p., and imaged by noninvasive bioluminescence imaging using an IVIS Lumina system (Caliper Life Sciences, Waltham, MA, USA), all of which developed tumors within 14 days (size: ∼55 mm^3^). For each experiment, mice were randomly distributed into equal groups (*n* = 10 mice/group) that were either untreated or treated with i.p. injections twice daily with 25 mg/kg/day or 100 mg/kg/day gefitinib, 50 mg/kg/day TV-6, or TV-6-based combined therapy involving low- or high-dose gefitinib for 21 consecutive days. The animals dosed appropriately were monitored daily for 3 months, and the objective response rate and survival were recorded. Animals were sacrificed because of progressive disease if TV was \>2500 mm^3^ before the next measurement. CR was defined as a complete regression of the tumor without any recurrence.

Statistical analysis {#s0035}
--------------------

Results are presented as the mean ± standard error of the mean (SEM) or standard deviation (SD). Predefined pairwise comparisons of treated group(s) with the control group for the indicated time points were conducted. Kaplan--Meier survival analysis and multivariate Cox regression were performed using the R survival package (<https://cran.r-project.org/web/packages/survival/index.html>) and re-plotted using Graphpad Prism software (v.6.00; GraphPad Software, La Jolla, CA, USA). Log ratios, unpaired *t* test *p*-values, and color-coded heat maps were obtained using MATRIX. For comparisons involving progressively resistant cell lines, analyses were performed using the R package by fitting a linear regression model to gene-expression data against the log-transformed 50% inhibitory concentration (IC~50~) values as measures of drug response. Weibull parametric survival analysis was used to test the interaction effect of each combination of drugs in groups to determine synergy, additivity, less than additivity, or antagonism of survival. Unless indicated, the mean ± SEM is reported. A p \< 0.05 was considered significant.

Results {#s0040}
=======

Residual LAD that resist oncogene ablation exhibits CSC-like features and relies on SIRT1 for survival {#s0045}
------------------------------------------------------------------------------------------------------

To establish in vitro models of LAD exhibiting EGFR-TKI resistance, the LAD cell lines PC9 and HCC827 demonstrating exquisite TKI sensitivity were treated long-term (\>6 months) with increasing doses of gefitinib. This allowed development of a PC9 cell series of T5, T10, T15, and T20 resistant variants ([Figure 1](#f0005){ref-type="fig"}A) and HCC827 isogenic cell series of T4, T8, T16, and T20 resistant variants ([Figure 1](#f0005){ref-type="fig"}B) that showed progressive increases in resistance to gefitinib along with increasing treatment cycles, subsequently reaching increases in IC~50~ for PC9 and HCC827 of T20 ([Supplementary Figure S1A and B; Supplementary Table S1](#s0100){ref-type="sec"}). Significantly, Aldefluor assay showed that the ALDH^bri+^ cell populations constituted ∼31.06% of PC9 ([Figure 1](#f0005){ref-type="fig"}C and [Supplementary Figure S1](#s0100){ref-type="sec"}C) and 27.64% of HCC827 T20 cells ([Figure 1](#f0005){ref-type="fig"}D and [Supplementary Figure S1](#s0100){ref-type="sec"}D), with CSCs clearly enriched in drug-resistant cell lines. Additionally, we conducted a sphere-formation assay to examine the cellular functional features of stem cell-like properties, finding that PC9 ([Figure 1](#f0005){ref-type="fig"}E and [Supplementary Figure S1](#s0100){ref-type="sec"}E) and HCC827 ([Figure 1](#f0005){ref-type="fig"}F and [Supplementary Figure S1](#s0100){ref-type="sec"}F) T20 cells acquired a higher ability to form spheres in suspension culture as compared with parental cells, indicating that T20 yielded small subpopulations of cancer cells capable of surviving high-concentration gefitinib exposure that kills the vast majority of cells, thereby reflecting phenotypic heterogeneity within the population.Figure 1Residual LAD resistant to EGFR ablation exhibit CSC features and rely on SIRT1 for survival. A and B, Dose-response curves for PC9 (A) and HCC827 (B) cells after long-term treatment with gefitinib. P, parental cell line; T\[n\], resistant variant generated after ''n'' cycles of gefitinib. Values on the X-axis indicate gefitinib concentration (μM). Each data point represents the mean ± SD of three replicates. C and D, Relative percentage of the ALDH^bri^ subpopulation of PC9 and HCC827 parental and T20 cells. E and F, Sphere-formation assay showing that PC9 and HCC827 T20 cells acquired an increased ability to form spheres in suspension culture relative to parental cells. G--I, PC9 (G), and HCC827 (H) T20 cells showed hypersensitivity to TV-6, as well as EX 527, as compared with parental cells. The result was the same as that for ALDH1^bri+^ cells (I) derived from relapsed LAD patients under gefitinib treatment. Each data point represents the mean ± SD of three replicates per drug dose.

To investigate the molecular changes accompanying the development of gefitinib resistance, we performed RNA sequencing of the entire progressively resistant isogenic PC9 and HCC827 cell series. We fitted a linear regression model to microarray data to systematically identify genes showing a progressive increase or decrease in expression consistent with increasing drug resistance as represented by the log-transformed IC~50~ values across the entire series of progressed lines. We identified 1849 differentially expressed genes in the PC9 resistant series and 1910 genes in the HCC827 resistant series at an FDR of 0.1 ([Supplementary Figure S1](#s0100){ref-type="sec"}G). We then performed stringent filtering of the expression data to select genes exhibiting an overlap between the two progressively resistant cell line models. We further required these changes to occur in vivo in primary cancerous tissue from patients that relapsed under gefitinib treatment. We identified 93 upregulated and 75 downregulated genes that overlapped between the two resistant cell line series ([Supplementary Figure S1](#s0100){ref-type="sec"}H), whereas intersection with primary tumor profiles ([Supplementary Figure S1](#s0100){ref-type="sec"}I) identified 40 upregulated and 21 downregulated genes exhibiting differences in expression that were sustained in vivo ([Supplementary Figure S1](#s0100){ref-type="sec"}J). These 61 genes ([Supplementary Figure S2](#s0100){ref-type="sec"}A) formed our preclinical resistance signature.

Notably, among the top-ranked gene list that was upregulated in therapy exposed samples, we focused on the gene encoding SIRT1, a histone deacetylase involved in numerous processes, including self-renewal and stemness maintenance and with particular functions in bioenergetic metabolism [@b0105]. To test the survival dependency of resistant clones on SIRT1, we applied highly selective SIRT1 inhibitors TV-6 and Selisistat (EX 527), findings that PC9 ([Figure 1](#f0005){ref-type="fig"}G) and HCC827 ([Figure 1](#f0005){ref-type="fig"}H) T20 cells showed higher sensitivity to these inhibitors as compared with parental cells. We then tested the pharmacologic sensitivity of ALDH1^bri+^ cells derived from relapsed LAD patients to SIRT1 inhibitors, and found that the IC~50~ values for this cell population after incubation were in a lower micromolar range than their ALDH1^low-^ counterparts ([Figure 1](#f0005){ref-type="fig"}I)

We then evaluated *SIRT1* expression levels in ALDH1^bri+^ cells from eight relapsed LAD patients, resistant to gefitinib, and sorted by ALDH activity. ALDH1^bri+^ cells displayed enhanced *SIRT1* expression as compared with that in ALDH1^low-^ counterparts ([Supplementary Figure S2](#s0100){ref-type="sec"}B). We then queried the entire progressively resistant PC9 ([Supplementary Figure S2](#s0100){ref-type="sec"}C) and HCC827 ([Supplementary Figure S2](#s0100){ref-type="sec"}D) series and found a consistent increase in *SIRT1* expression along with increasing resistance to TKI therapy.

To evaluate whether the hypersensitivity of TKI-resistant cells was specific to SIRT family inhibitors or represented a general epigenetic susceptibility, we tested other compounds inhibiting JmjC-lysine demethylase (KDM), lysine-specific histone demethylase 1, histone methyltransferases, histone acetyltransferases, bromodomains, DNA methyltransferases, or histone deacetylases. We did not observe significant differences in IC~50~ values for any of these drugs between parental cells and resistant variants ([Supplementary Figure S3](#s0100){ref-type="sec"}A). These results uncovered a specific, targetable vulnerability to SIRT inhibition that can be exploited to treat LADs exhibiting resistance to TKI therapy.

LAD treated with EGFR inhibitors are addicted to mitochondrial oxidative metabolism {#s0050}
-----------------------------------------------------------------------------------

GSEA of the rank-ordered genes associated with drug sensitivity revealed prominent expression of genes governing hypoxia, autophagy, lysosome activity, and insulin secretion, as well as strong reliance on mitochondrial respiration for cellular energetics ([Supplementary Table S2](#s0100){ref-type="sec"}). Considering that malignant transformation involves cellular metabolic changes, which could in turn render the transformed cells susceptible to specific assaults in a selective manner, we searched for such vulnerabilities in LAD.

Accordingly, in resistant PC9 and HCC827 T20 cells, the basal and maximal respiratory capacities of their CSC fractions were higher than those in their parental counterparts, suggesting activated mitochondrial (mt)OXPHOS ([Figure 2](#f0010){ref-type="fig"}A). Consistent with this result, mitochondrial membrane potentials (mtMPs) were also upregulated in PC9 and HCC827 T20 cells ([Figure 2](#f0010){ref-type="fig"}B). We then measured the levels of reactive oxygen species (ROS), which can be elevated through the activation of the electron transport chain in the mitochondria. Hydrogen peroxide (H~2~O~2~) and mitochondrial superoxide levels were elevated in PC9 and HCC827 T20 cells as compared with parental cells, which was in line with hyperactive mtOXPHOS ([Figure 2](#f0010){ref-type="fig"}C and D). Moreover, ALDH1^bri+^ cells derived from residual LAD tumors following TKI therapy also exhibited elevated mtOXPHOS capacity, mtMPs, ROS levels, and mitochondrial superoxide levels as compared with their ALDH1^low-^ counterparts ([Figure 2](#f0010){ref-type="fig"}A--D). PC9 and HCC827 T20 cells were then sorted for high versus low mtMPs by the intensity of MitoTracker Red CMX Ros and plated as spheres, revealing that sphere formation was markedly higher in cells with high mtMPs as compared with low mtMPs ([Figure 2](#f0010){ref-type="fig"}E).Figure 2LAD CSCs exhibit an enhanced mitochondrial respiratory phenotype. A, OCRs were determined in a panel of LAD T20 and parental cells. B, LAD T20 and parental cells were stained with Mito Tracker Red CMX Ros and analyzed by flow cytometry. C, ROS levels were determined by ROS-Glo, as described in the STAR Methods. D, Cells were stained with Mito SOX Red and analyzed by flow cytometry. E, PC9 and HCC827 T20 cells were sorted by flow cytometry according to the intensity of Mito Tracker Red CMX Ros and then seeded for sphere assays. F, Relative percentage of the ALDH^bri^ subpopulation of PC9 T20 cells under oligomycin A (OM) treatment at the indicated concentrations. G, PC9 T20 cells were treated with gefitinib (Gef) and/or OM at the indicated concentrations. Annexin V was used as a marker of cell death. A representative result from three independent flow cytometry experiments is shown. Data represent then mean ± SD.

To test the survival dependency of resistant clones on mtOXPHOS, we employed the mitochondria-targeted inhibitor tigecycline [@b0110], which suppress mitochondrial DNA (mtDNA) translation, and oligomycin A [@b0050], an ATP synthase inhibitor ([Supplementary Figure S4](#s0100){ref-type="sec"}A). PC9 ([Supplementary Figure S4](#s0100){ref-type="sec"}B) and HCC827 ([Supplementary Figure S4](#s0100){ref-type="sec"}C) T20 cells were several-fold hypersensitized to mitochondria-targeted inhibitors as compared with their corresponding parental cells. Moreover, targeting mitochondria with oligomycin A attenuated sphere formation ([Supplementary Figure S4](#s0100){ref-type="sec"}D) and the ALDH1^bri+^ subpopulation ([Figure 2](#f0010){ref-type="fig"}F and [Supplementary Figure S4](#s0100){ref-type="sec"}E)) by resistant CSC clones. Similarly, tigecycline reduced sphere formation ([Supplementary Figure S4](#s0100){ref-type="sec"}F) and the ALDH1^bri+^ fraction ([Supplementary Figure S4](#s0100){ref-type="sec"}G). Even treatment with extremely low doses of mitochondria-targeted inhibitors blocked the enrichment of ALDH1^bri+^ cells. These results suggested that resistant clones exhibiting CSC features relied upon mtOXPHOS for survival.

We then determined whether inhibition of mitochondrial respiration could counteract the intrinsic drug resistance mediated by CSC clones. At low-doses, single-agent oligomycin A or tigecycline administration did not induce substantial cell death, as measured by flow cytometry in PC9 T20 cells; however, when combined with gefitinib, the overall number of dead cells significantly increased. Indeed, in the presence of gefitinib, the lower dose of mitochondria-targeted inhibitors was equally effective as the higher dose ([Figure 2](#f0010){ref-type="fig"}G and [Supplementary Figure S4](#s0100){ref-type="sec"}H). These findings suggested that resistant CSCs were susceptible to the inhibition of the mitochondrial respiratory chain, and that oxidative metabolism could represent a prime target for overcoming TKI resistance in LAD.

The role of SIRT1 in the mitochondrial metabolism phenotype of TKI-resistant CSCs in LAD {#s0055}
----------------------------------------------------------------------------------------

To identify potential factors that regulate mtOXPHOS-mediated metabolic changes that occur in response to TKI exposure, we evaluated the effects of lentiviral vector-mediated short-hairpin (sh)RNA knockdown of *SIRT1* in PC9 and HCC827 T20 cells, which was confirmed by immunoblot after use of two independent shRNAs for each gene ([Supplementary Figures S5](#s0100){ref-type="sec"}A and B). Knockdown of *SIRT1* reduced mitochondrial respiratory capacities in PC9 and HCC827 T20 cells ([Figure 3](#f0015){ref-type="fig"}A). Additionally, mtDNA content was reduced upon SIRT1 ablation in PC9 and HCC827 T20 cells ([Figure 3](#f0015){ref-type="fig"}B). Moreover, transfection of *SIRT1* shRNA into PC9 and HCC827 T20 cells reduced ROS ([Figure 3](#f0015){ref-type="fig"}C) and mtMPs ([Figure 3](#f0015){ref-type="fig"}D) levels, and reductions in sphere formation ([Supplementary Figure S5](#s0100){ref-type="sec"}C) and the ALDH1^bri+^ fraction ([Supplementary Figure S5](#s0100){ref-type="sec"}D) were also observed in PC9 and HCC827 T20 cells following SIRT1 ablation.Figure 3Inhibition of SIRT1 inhibits the mtOXPHOS dependency of CSCs. A, OCRs were determined by a Seahorse XFe96 extracellular flux analyzer. B, mtDNA levels were measured by real-time quantitative PCR. C, ROS levels were determined by ROS-Glo. D, LAD cell lines were stained with MitoTracker Red CMX Ros and then analyzed by flow cytometry. E, Relative percentage of the ALDH^bri^ subpopulation in PC9 T20 cells under TV-6 treatment at the indicated concentrations. F, PC9 T20 cells were seeded for sphere assays (40×) and were treated with DMSO or tigecycline ± DOX. The inhibitory effect of tigecycline on sphere formation was abolished in PC9 T20 cells expressing DOX-inducible SIRT1 as compared with uninduced cells. Scale bar = 500 μm. G, Flow cytometric determination of the frequency of the Annexin V^+^ cell fraction in PC9 T20 cells treated with gefitinib (Gef) and/or TV-6 at the indicated concentrations. Annexin V was used as a marker of cell death. A representative result from three independent flow cytometry experiments is shown.

We then determined whether SIRT inhibitors could produce similar antitumor effects as observed with genetic strategies. To this end, we used the SIRT1 inhibitors TV-6 and EX 527. Similar to SIRT1 ablation, TV-6 reduced sphere formation ([Supplementary Figure S5](#s0100){ref-type="sec"}E) and the ALDH1^bri+^ fraction ([Figure 3](#f0015){ref-type="fig"}E and [Supplementary Figure S5](#s0100){ref-type="sec"}F) of PC9 and HCC827 T20 cells and was associated with decreased oxygen consumption rate (OCR) ([Supplementary Figure S5](#s0100){ref-type="sec"}G), and mtMP ([Supplementary Figure S5](#s0100){ref-type="sec"}H). Similarly, EX 527 decreased sphere formation ([Supplementary Figure S5](#s0100){ref-type="sec"}I) and the ALDH1^bri+^ fraction ([Supplementary Figure S5](#s0100){ref-type="sec"}J) of PC9 and HCC827 T20 cells and inhibited mitochondrial respiratory capacity as assessed by OCR ([Supplementary Figure S6](#s0100){ref-type="sec"}A) and mtMP ([Supplementary Figure S6](#s0100){ref-type="sec"}B).

Additionally, we found that the inhibitory effect of tigecycline on sphere formation was rescued in PC9 T20 cells expressing doxycycline (DOX)-inducible *SIRT1* as compared with uninduced control cells ([Figure 3](#f0015){ref-type="fig"}F). Furthermore, the inhibitory effect of oligomycin A on stemness maintenance was also abolished in PC9 T20 cells stably overexpressing *SIRT1* as compared with control cells, suggesting that the tumor-initiating capacity potentiated by SIRT1 relies on mtOXPHOS ([Supplementary Figure S6](#s0100){ref-type="sec"}C). These results implied that SIRT1 potentiated mtOXPHOS and subsequent CSC enrichment.

Consequently, we then determined whether eliminating *SIRT1* expression could affect the responsiveness of LAD cells to anticancer drugs. Indeed, high-dose TV-6 modestly increased apoptosis in PC9 T20 cells resistant to TKI treatment, with this accompanied by a significant sensitization to gefitinib therapy. At a lower-dose, single-agent TV-6 did not induce substantial cell death in PC9 T20 cells; however, the sensitization to anticancer approaches with low-dose TV-6 in resistant cells was comparable to that achieved by high-dose treatment ([Figure 3](#f0015){ref-type="fig"}G). Additionally, we confirmed SIRT1 inhibition as a combinatorial strategy to sensitize gefitinib-induced cell death using EX 527 ([Supplementary Figure S6](#s0100){ref-type="sec"}D).

Collectively, these findings indicated that SIRT1 inhibition enhanced the targeting of resistant CSCs in combination with molecular-targeted drugs in LAD.

TV-6 selectively targets CSCs and acts together with gefitinib to block tumor growth and prolong remission {#s0060}
----------------------------------------------------------------------------------------------------------

We tested the *in vivo* effect of TV-6, gefitinib, and the combination of both on primary human PDXs initiated from a sample from a TKI-refractory LAD patient and engrafted in NSG mice. We first evaluated the pharmacokinetics of TV-6 in mice ([Supplementary Figure S7](#s0100){ref-type="sec"}A), subsequently choosing a treatment schedule of twice-daily i.p. injections. Following engraftment, mice (*n* = 10 mice/group) were treated after 14 days with a 3-week course of gefitinib (100 mg/kg/day), TV-6 (50 mg/kg/day), both drugs combined and vehicle only ([Supplementary Figure S7](#s0100){ref-type="sec"}B). We observed a synergistic response from combined TV-6 and gefitinib treatment of tumors arising after 14 days. After 15 days of treatment, the drug combination virtually eliminated tumors, whereas injection of gefitinib alone had little effect on tumor remission. Moreover, mice treated with TV-6 alone showed reduced tumor growth relative to that observed in untreated or gefitinib-treated mice, and after day 20, we observed only modest tumor regression. Furthermore, combined treatment resulted in further reductions in TV after an additional 20 days. In mice treated with TV-6 alone, tumor growth was suppressed until day 40, after which tumor growth resumed and/or showed signs of relapse at rates near those observed in untreated control mice, whereas the majority of mice receiving combined treatment with TV-6 and gefitinib sustained low engraftment following drug withdrawal along with no detectable tumor for at least 65 days ([Figure 4](#f0020){ref-type="fig"}A and B). In all experimental arms, we observed no changes in the appearance or behavior of the mice or signs of myelosuppression ([Figure 4](#f0020){ref-type="fig"}C), thereby confirming excellent tolerability. Additionally, we found no alterations in serum levels of liver, muscle, or cardiac enzymes ([Figure 4](#f0020){ref-type="fig"}D).Figure 4SIRT1 inhibitor(s) target CSCs and act synergistically with gefitinib to reduce tumor growth in vivo. A and B, Representative images of subcutaneous PDXs in mice at day 40 for each group. Plots of tumor-growth curves. There was a significant size reduction in tumors treated with TV-6 or both TV-6 and gefitinib as compared with that in control or gefitinib-only groups. C, The total white blood cell count in mice after discontinuation of treatment. D, Serum levels of liver enzymes \[alkaline phosphatase (ALP), aspartate aminotransferase (AST), and creatine kinase (CK)\] in mice from each group. Lines represent medians. E, Cells were dissociated from tumors and subjected to Aldefluor assay. The percentage of ALDH^bri^ cells is shown. F, Survival of mice from (A) after discontinuation of treatment. G and H, The viability of PC9 T20 cells after different treatments with gefitinib (Gef) combined with TV-6 (G) or tigecycline (H) according to MTS assay. Data were analyzed with CalcuSyn software to generate a CI versus fractional effect (cell death) plot showing the effect of the combination of Gef with TV-6 or tigecycline. CI \< 1 indicates synergism.

Importantly, the ALDH1^bri+^ fraction in residual PDXs decreased, although marginally, in gefitinib-treated mice but significantly in mice treated with TV-6, with further reductions observed in mice receiving combined treatment with both drugs ([Figure 4](#f0020){ref-type="fig"}E), indicating that TV-6 was active against CSCs. Secondary transplantation of residual tumor from mice receiving combined treatment resulted in significantly reduced engraftment relative to single agents, indicating a reduced CSC capacity of residual cells. Additionally, TV-6 resulted in abrogation of secondary engraftment, whereas gefitinib treatment alone did not significantly affect engraftment in secondary recipients or CSC frequency ([Supplementary Table S3](#s0100){ref-type="sec"}). Furthermore, mice treated with TV-6 demonstrated significantly improved survival after discontinuation of therapy as compared with control or gefitinib-treated mice, and combined therapy further increased survival as compared with single agent alone ([Figure 4](#f0020){ref-type="fig"}F).

We also evaluated the efficacy of TV-6 or tigecycline in combination with gefitinib using the CalcuSyn median effect model, where the combination index (CI) indicates synergism (CI \< 0.9), additivity (CI = 0.9--1.1), or antagonism (CI \> 1.1). Combined treatment with TV-6 and gefitinib showed an additive or synergistic effect; however, when TV-6 was added either before or after gefitinib, the combinatorial effect was clearly synergistic ([Figure 4](#f0020){ref-type="fig"}G). Similarly, treatment effects with tigecycline in combination with gefitinib were additive or synergistic, regardless of drug sequence ([Figure 4](#f0020){ref-type="fig"}H). Our findings suggest important implications for tumor treatment and pave the way for targeting OXPHOS or SIRT1 in association with oncogenic pathway inhibitors to eradicate CSCs and prevent tumor relapse in LAD.

TV-6 reduces the gefitinib dose necessary to prolong remission and decrease lung colonization {#s0065}
---------------------------------------------------------------------------------------------

Because cytotoxic therapy is toxic and causes unwanted and often serious side effects in cancer patients [@b0115], a major challenge is to lower the doses of TKIs without decreasing their effectiveness. We reasoned that the combinatorial effect of TV-6 might permit lowering of the gefitinib dose. To test this hypothesis, we transplanted nude mice subcutaneously with PC9 cells carrying a luciferase reporter and evaluated the effects of a 3-week course of scheduled treatments starting 14 days later when tumors were already palpable (*n* = 10 mice/group). We administered gefitinib (100 mg/kg/day), TV-6 (50 mg/kg/day), both drugs combined, as well as TV-6-based combinatorial therapy involving a four-fold reduced concentration of gefitinib (25 mg/kg/day instead of 100 mg/kg/day) ([Supplementary Figure S8](#s0100){ref-type="sec"}A). As monotherapies, treatment of PC9 xenografts with higher-dose gefitinib suppressed tumor growth but did not prevent relapse. However, the reduced dose of gefitinib alone was less effective, as tumor regression was not observed. Interestingly, combined treatment with TV-6 and the reduced dose of gefitinib resulted in complete tumor regression and no detectable relapse for at least 65 days. Indeed, in the presence of TV-6, the lower dose of gefitinib was equally as effective as the higher dose in prolonging remission ([Figure 5](#f0025){ref-type="fig"}A--C).Figure 5TV-6 reduces the gefitinib dose necessary to prolong remission and decrease lung colonization. A and B, Normalized bioluminescence signals of tumor remission and representative bioluminescence images of mice injected subcutaneously with PC9 cells carrying a luciferase reporter and treated with different dosage schedules at day 40 post-administration. The data represent the average ± SEM. C, Tumor-growth curves of tumor-bearing nude mice following receipt of the indicated dosage schedules. D and E, Normalized bioluminescence signals of lung metastatic nodules and representative bioluminescence images of lungs injected with PC9 cells carrying a luciferase reporter and treated with different dosage schedules at day 35 post-administration. Data represent the average ± SEM. F, Column scatter plot showing the number of surface metastases per lung in mice receiving the indicated dosage schedules. G, Tumor infiltration into lung tissue in nude mice treated with different schedules was analyzed at 15 and 35 days post-administration of drug(s) according to H&E-stained lung sections. Scale bar = 100 μm.

We then determined the effect of different dosing schedules on the lung engraftment of PC9 cells intravenously injected into the tail of nude mice ([Supplementary Figure S8](#s0100){ref-type="sec"}B). For imaging of lung metastatic activity and distribution, mice were viewed dorsally and ventrally by bioluminescence imaging weekly, as well as by examination of the lungs at necropsy.

A single dose of TV-6 was more effective at inhibiting tumor colonization than gefitinib alone at a dose of 25 mg/kg. Moreover*,* 100 mg/kg gefitinib as a single agent potently lowered lung bioluminescence signals, whereas low-dose gefitinib mice were moribund and presented enlarged lung engraftment of GFP^+^ cells, which did not occur in mice receiving high-dose therapy*.* Indeed, decreased engraftment upon treatment was sharply accelerated by combined treatment with TV-6 and gefitinib, with a slightly more pronounced effect observed with the higher gefitinib dose than the lower dose. However, the absence of relapse due to TV-6 therapy was comparable at both doses of gefitinib for the period of the experiment. A double dose of gefitinib plus TV-6 substantially reduced long-term lung engraftment, and the number of colonies remained at almost undetectable levels, even after up to 53 days ([Figure 5](#f0025){ref-type="fig"}D and E; [Supplementary Figure S8](#s0100){ref-type="sec"}C). These preclinical observations suggested the possibility of using SIRT1 inhibitors to lower the gefitinib dose in LAD patients.

Similar to the results obtained from bioluminescence lung-colonization experiments, mice treated with high-dose gefitinib monotherapy or combined TV-6 and gefitinib showed a dramatic decrease in the number of nodules and incidence of lung metastasis as compared with mice treated with other schedules ([Figure 5](#f0025){ref-type="fig"}F)*.* Furthermore*,* decreased frequency of metastasis was confirmed by a significant reduction in histologically determined organ infiltration of tumor cells into the lungs of these mice relative to that observed in those bearing more nodules. The infiltration of tumor cells between different dosages was more pronounced at 21 days after drug withdrawal when low-dose gefitinib-treated mice were moribund and displayed massive lung infiltration of tumor cells, which did not occur in those receiving high-dose therapy and/or combined treatment ([Figure 5](#f0025){ref-type="fig"}G).

These results indicated that adding mitochondrial inhibitors to first-line TKI treatment significantly diminished the number of cells with high re-population and invasion potential, and that even relatively low-dose TKI treatment could yield a sustained antitumor effect.

Inhibition of metabolic activity prevents the development of drug resistance {#s0070}
----------------------------------------------------------------------------

Given the hypersensitivity of TKI-resistant cells to metabolic inhibitors and the metabolic reprogramming present in resistant cells, we determined whether metabolic inhibitors and TKI therapy could synergistically prevent the emergence of acquired drug resistance. We examined the ability of a subset of putative anticancer compounds to prevent the emergence of tolerant colonies by co-treating cultures continuously with gefitinib and these compounds. Among the tested compounds, three different SIRT1 inhibitors as well as mitochondrial metabolism inhibitors virtually eliminated the emergence of drug-tolerant colonies from PC9 cells during antitumor treatment, whereas other tested agents did not in the presence of gefitinib ([Figure 6](#f0030){ref-type="fig"}A and B). This result presented a new therapeutic opportunity for not only targeting resistant LADs but also to possibly prevent the emergence of resistant subpopulations and achieve greater response from sensitive LADs treated with first-line TKIs. Upon pretreatment of naïve PC9 cells with tigecycline for 5 days, followed by immediate removal of the inhibitor before isolating individual cells by transfer to six-well plates, we were unable to detect any TKI-tolerant clones ([Figure 6](#f0030){ref-type="fig"}C). However, pretreatment of naïve cells and removal of the inhibitor 72 h prior to isolating individual cells allowed detection of TKI-tolerant clones in a proportion similar to that observed in control naïve cells ([Figure 6](#f0030){ref-type="fig"}D), suggesting that drug-tolerant cells were continuously replenishing in the absence of agents eliminating them. This suggested that pre-existing TKI-tolerant cells in naïve LAD populations are highly metabolism dependent.Figure 6Preventing the Establishment of Drug-Tolerant Clones. A, PC9 cells were either untreated or treated alone with the indicated pharmacological agents for 7 days (top rows) or with Gefitinib (Gef) alone or the combination of the indicated agent with Gefitinib for 40 days (bottom rows). Fresh media with drugs were provided every 3 days. Following treatment, plates were fixed and stained. All experiments were performed in triplicate and representative plates are shown. B, Individual colonies were counted and the quantified results were graphed. In some cases the colonies were too numerous to count (indicated as \> 500 colonies). Error bars represent standard deviations from the mean of three independent experiments. C, PC9 cells were either treated with Gefitinib (Gef) for 30 days or pretreated for 5 days with Tigecycline and then immediately treated with Gefitinib for 30 days, plates were fixed and stained. D, PC9 cells were either treated with Gefitinib for 30 days, in addition, pretreated for 5 days with Tigecycline, then removed the inhibitor 72 hours prior to Gefitinib treatment for 30 days. Plates were fixed and stained. The experiment was performed in triplicate and representative plates are shown.

Clinical significance of the expression of SIRT1 and mtOXPHOS components in LAD patients {#s0075}
----------------------------------------------------------------------------------------

We used an independent series of tumors derived from LAD patients sensitive to first-generation TKIs or exhibiting relapse characteristics under gefitinib treatment to determine levels of SIRT1, ALDH1, and widely accepted stem cell markers of lung cancer and a subset of mtOXPHOS components by immunohistochemistry (IHC) ([Figure 7](#f0035){ref-type="fig"}A). These mtOXPHOS proteins include, cytochrome C oxidase IV, a component of mitochondrial complex IV and a frequently used marker for mitochondrial content, PGC1α, a transcriptional coactivators that promotes energy metabolism and ROS detoxification, and mitochondrial ribosomal protein S5, which localizes to the mitochondria and promotes complex-I function and NAD^+^ generation to enhance mitochondrial respiration. Our results identified markedly higher levels of SIRT1, ALDH1, and mtOXPHOS components in sections from post-relapse tumor tissues as compared with TKI-naïve samples.Figure 7Clinical significance of the expression of SIRT1 and mtOXPHOS components in LAD patients. A, Representative results of IHC staining for SIRT1, mtOXPHOS components, and ALDH1. Case 1 (upper panel): sample from a post-relapsed LAD patient under gefitinib treatment; and case 2 (lower panel): TKI-naïve LAD sample harboring an EGFR mutation. Scale bar, 25 μm. B, Based on IHC staining results, clinical samples were divided into two groups: SIRT1^high^/ALDH1^high^ and SIRT1^low^/ALDH1^low^. Multivariate logistic regression analysis of the odds ratios for different clinicopathological characteristics showed that compared with the low profile, patients with the high profile had a higher risk of large tumor size, recurrence, metastases, and cancer embolus. C, Kaplan--Meier analysis of the association between SIRT1/ALDH1 levels and the overall survival rate of LAD patients. ***D,*** A theoretic model underlying the role of the SIRT1-mtOXPHOS axis in LAD metabolic reprogramming and stemness maintenance. Evaluation of LAD cell populations treated with the TKI inhibitor gefitinib identified unique aspects of a subpopulation of tumor cells exhibiting stem-like properties and mitochondria-specific metabolic features along with their reliance on sirtuin 1 (SIRT1) for survival advantage. Inhibition of SIRT1 and mitochondrial oxidative phosphorylation (mtOXPHOS) blocks CSC expansion and restores TKI sensitivity.

We then analyzed the clinical relevance of SIRT1 and CSC-marker expression in human LAD samples. Based on the expression levels, samples were divided into two groups (SIRT1/ALDH1^high^ and SIRT1/ALDH1^low^). SIRT1 and ALDH1 expression was significantly associated with multiple aggressive clinicopathological characteristics, such as large tumor size, high recurrence and metastasis rates, and cancer embolus ([Figure 7](#f0035){ref-type="fig"}B). Moreover, Kaplan--Meier survival analysis indicated that compared with the SIRT1/ALDH1^low^ profile, LAD patients with the SIRT1/ALDH1^high^ profile had a much worse prognosis ([Figure 7](#f0035){ref-type="fig"}C).

These data suggested that the SIRT1/mtOXPHOS protein axis plays a critical role in predicting resistance to TKI and poor prognosis in LAD patients.

Discussion {#s0080}
==========

Targeting oncogene-driven signaling pathways represents a clinically validated approach to treating several devastating diseases; however, despite such treatments resulting in significant tumor shrinkage, the frequency of relapse remains. Insights into the limitations of targeted kinase therapy were obtained from understanding that LAD comprises differentiated cells, as well as a higher fraction of spherogenic and tumorigenic undifferentiated cells that survive shutdown of oncogenic signaling and are capable of propagating the disease [@b0005], [@b0015]. Using multiple treatment cycles, we developed a series of progressively resistant cell lines representing different oncogenotypes, followed by molecular characterization of the entire series and identification of novel pathways involving an increased dependency on mitochondrial biogenesis and oxidative phosphorylation. Previous studies also revealed a metabolic vulnerability to tumor recurrence following neoadjuvant chemotherapy via molecular profiling of residual disease [@b0120], [@b0125].

Tumor cells reprogram a variety of central metabolic and bioenergetic pathways to maintain exacerbated growth and survival rates [@b0030]. Several recent reports explored mitochondrial respiration specificities as targetable susceptibilities of cytotoxic drug-selected CSCs, which when exploited, should be synthetically lethal when combined with established therapies [@b0040]. For example, residual breast cancers after conventional chemotherapy display mtOXPHOS, as well as tumor-initiating features [@b0130]. Mammospheres obtained from hormone-dependent, estrogen-receptor-positive breast cancer exhibit upregulation of key mitochondrial enzymes involved in β-oxidation and ketone metabolism [@b0135], suggesting that CSC metabolism relies on mitochondrial respiration. Vazquez et al. [@b0140] report reduced glycolysis and increased OXPHOS in certain melanomas, revealing metabolic plasticity rather than stable Warburg pathophysiology. Furthermore, Haq [@b0055] reported that increased OXPHOS is required for melanomas to survive BRAF inhibition, suggesting the potential benefit of investigating therapeutic combinations of BRAF inhibitors with metabolism-related inhibitors. Other studies [@b0045], [@b0145], [@b0150] showed that leukemic primitive cells rely more heavily on OXPHOS to supply their energetic demands as compared with bulk tumor cells, thereby suggesting a link between mitochondrial pathophysiology and therapy resistant clones and representing an attractive topic for future investigation. Furthermore, using single-cell RNA sequencing coupled with a highly sensitive BCR--ABL-detection method, Giustacchini et al. [@b0155] showed that primitive BCR--ABL^+^ cells from chronic myelogenous leukemia (CML) patients presented an overexpression of OXPHOS- and fatty acid β-oxidation-related genes as compared with BCR-ABL^−^ counterparts. This suggests that the oxidative phenotype characterized in the present study is specific to leukemia stem cells in patients, further highlighting the clinical relevance of our findings. Our findings identified an adaptive metabolic program that limits the therapeutic efficacy of EGFR inhibitors. Intrinsic resistance conferred by metabolic specificities could represent an additional protective mechanism that helps cells survive the initial contact with various cytotoxic agents and provides cells with added survival time to establish longer-lasting secondary resistance mechanisms ([Figure 7](#f0035){ref-type="fig"}D).

A previous study demonstrated that SIRT1 deacetylates the mitochondrial master regulator PGC-1α to enhance mtDNA replication and biogenesis [@b0160]. Interestingly, PGC-1α inhibition did not directly inhibit CML hematopoiesis, suggesting that additional SIRT1-related mechanisms besides regulation of mitochondrial respiration are also involved in promoting CML stem cell growth. Although the role of SIRTs in oncogenesis varies based on tissue type, recent evidence revealed a critical function for SIRT1 in regulating p53 deacetylation in CML-specific escape from imatinib therapy [@b0100]. To gain further insights into SIRT1, they extended their findings and proposed a mechanism involving a positive feedback loop between SIRT1 and c-MYC in regulating acute myeloid leukemia (AML) stem cells harboring a FLT3 internal tandem duplication mutation [@b0095]. In the future, it will be of interest to explore interactions between SIRT1 regulation of metabolism and its regulation of p53 and c-MYC and those effects on CSCs in LAD. Although changes in chromatin in our study were reminiscent of an established model of drug-tolerant lung cancer cells, the underlying mechanisms appeared distinct, as we did not observe enrichment of KDM5A in LAD cells that survived acute, short-term exposure to an EGFR inhibitor [@b0165]. It is possible that additional chromatin-modifying enzymes contribute to TKI tolerance in various experimental contexts. A plausible explanation is the involvement of unknown oncogenic signaling pathways activated by *EGFR* mutants that arise from the adaptation of cells from prolonged exposure to TKIs. The discrepancy further highlights the importance of understanding under which cellular context and protein complexes these enzymes act and suggests that differences in genetic backgrounds, culture conditions, specific oncogenes present, and the use of knockdown constructs versus the study of knockout cells must be taken into account.

Interestingly, it was recently reported that a subpopulation of pancreatic cancer cells that had survived Kras ablation were also mainly dependent on OXPHOS [@b0060]. Similarly, treatment of *BRAF*-mutated melanomas with BRAF inhibitors renders them addicted to OXPHOS [@b0050], [@b0055]. This observation together with the results of the present study indicate that in oncogene-expressing tumors, there exists a small subpopulation endowed with tumorigenic potential, self-renewal capabilities, intrinsic resistance to targeted therapies, high hyperpolarized mitochondria, and increased consumption of oxygen. By contrast, another study found that human CSCs derived from a large panel of PDX models carrying activating KRAS mutations identical to those found in their bulk counterparts bear distinct metabolic phenotypes with limited plasticity and controlled by MYC [@b0170]. Strikingly, CSCs from a second PDX model carrying wild-type KRAS showed a similar metabolic phenotype, further corroborating that the lack of plasticity is independent of KRAS mutational status. Moreover, KRAS-ablated cells require reactivation of mutant KRAS for proliferation and tumor relapse, suggesting that the observed OXPHOS phenotype is restricted to oncogene-ablated dormant cells (as described in the present study), as opposed to the highly tumorigenic CSCs studied by others. The metabolic phenotype of CSCs appears not to be universal but rather varies according to context. Elucidating the molecular basis for this specificity with regard to differential oncogenic reprogramming of cellular metabolism will be the next critical step in understanding tumor heterogeneity and complexity.

The CSC hypothesis is based on the differential tumor-forming properties and responses to well-defined therapy [@b0175]. A prediction of this model, heretofore untested, is that drugs that selectively inhibit CSCs should function synergistically with well-defined drugs to prolong the therapeutic response and make them more susceptible to a second drug. Additionally, it might have a potential use in preventing the development of drug tolerance, as opposed to treating resistance that has already occurred. Based on our findings, the addiction to OXPHOS treated with EGFR-targeted therapy suggests that mitochondrial inhibitors should be evaluated in combination with EGFR-pathway inhibitors *in vivo*. Upon drug withdrawal, we observed regression of transplanted tumors following single-agent treatment within 2 to 3 weeks, followed by relapse after 5 to 6 weeks; however, combinatorial therapy involving TV-6 prevented relapse for at least 2 months and indeed might have even represented a cure for these xenograft-generated tumors. Another major problem that cancer patients face is the high toxicity of conventional and molecular-targeted drugs that manifest as anemia, appetite changes, fatigue, hair loss, nausea, vomiting, and fertility changes [@b0115]. By contrast, lower doses of these well-defined therapeutics are ineffective at suppressing tumor burden. Therefore, identification of agents that can be combined with lower doses of existing therapeutics is of high clinical relevance. Although TV-6 is not a candidate for drug development targeting tumor regression, our observations support further investigation of SIRT1 inhibition as an approach for targeting LAD CSCs in combination with TKI treatment. TV-6 exhibited comparable effects in preventing relapse and prolonging the therapeutic response when combined with a four-fold reduced dose of gefitinib, which was ineffective as a monotherapy. Therefore, TV-6 exhibited broad anticancer effects of potential utility in a wide variety of clinical contexts for both cancer treatment and lowering the toxicity associated with first-line TKI therapy. Recent studies focusing on tolerance to SIRT1 inhibitors showed that TV-6 appeared more tolerable to normal hematopoietic progenitor cells according to multiple endpoints, and that applying it as a treatment in combination with the BCR-ABL TKI imatinib promoted eradication of CML stem cells in mouse models [@b0095], [@b0100]. Within the limited scope of the present study, we observed no changes in body or spleen weight or signs of toxicity during treatment, and total bone marrow cellularity was unaffected in all experimental arms, thereby confirming excellent tolerability. These observations, although preliminary, indicate promising avenues for further investigation toward using a combination of TV-6 and gefitinib to eliminate residual CSCs, as well as determine the safety and tolerability in patients with LAD who are in cytogenetic remission with evidence of residual EGFR^+^ cells. Furthermore, our model identified clinically relevant mechanisms of drug resistance; therefore, the mouse model could be a surrogate for acquired TKI drug resistance, as it captures cells that persist following a single cycle of TKI therapy and could, therefore, mimic a patient that clears the vast majority of the bulk population but experiences regrowth of disease within months of starting therapy. Additionally, the model could offer insight into mechanisms of relapse. The high OXPHOS status not only correlated with the probability of achieving remission with induction TKI therapy in an independent dataset of patients with LAD but also correlated with overall survival, thereby supporting the clinical relevance of our findings. Moreover, this model is compatible with recent findings by Farge et al. [@b0145], which demonstrated an *in vivo* approach to identifying primary AML cells that persist in the bone marrow after chemotherapy. In that study, mice were engrafted with tumor cells and then treated with cytarabine at an appropriate dose and schedule to reduce the level of tumor burden. On the time-interval of maximal depletion of tumor cells, the residual disease that persisted in the mouse bone marrow was isolated and studied.

Some potential limitations should be considered in our findings. First, the *in vitro* and *in vivo* studies of CSC response to TKIs and SIRT1 inhibitors were confined to a relatively small number of patient samples. Consequently, these data are not robust, and the results must, therefore, be interpreted with due caution. Additionally, LAD CSC populations vary from patient to patient, which can directly affect the response or resistance of these cells to single and combined treatments. Another consideration is the off-target effects of the SIRT1 inhibitor. All SIRT inhibitors, including TV-6, suppress more than SIRT1 [@b0180]; therefore, results from use of SIRT inhibitors should be interpreted with multiple enzymes in mind. This raises the question as to whether functional redundancy exists within SIRT families based on sequence homologies and architectural similarities. Although difficult to reconcile, discrepancies might at least be due to the fact that no study has demonstrated selective inhibition of the SIRT1 deacetylase, despite recent studies of several mechanism-based inhibitors targeting SIRT histone deacetylases. Although we cannot exclude the possibility that TV-6 also suppresses other SIRTs, these results could also be faithfully reproduced using an independent SIRT1 shRNA approach and tumor cells to distinguish the phenocopying effects of the chemical inhibitor. This could support SIRT1 as at least one target mediating TV-6 effects. Even with these considerations, the clinical implication of this work provides a supportive rationale to blocking the mtOXPHOS pathway in *EGFR*-mutant LAD patients and specifically in those who developed resistance under anti-EGFR therapy. Further work will reveal whether there are practical opportunities for synthetic lethality by pharmacology limiting the adaptive ability of transformed cells to upregulate OXPHOS when facing stress, such as oncogenic kinase inhibition.
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